These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35876022)

  • 21. Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease.
    Amioka M; Sanada R; Matsumura H; Kinoshita H; Sairaku A; Morishima N; Nakano Y
    Int J Cardiol; 2023 Jan; 370():294-299. PubMed ID: 36174820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
    Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS; Correa A; Contreras JP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.
    Carnicelli AP; Mentz RJ
    Circulation; 2021 Jan; 143(4):322-325. PubMed ID: 33493029
    [No Abstract]   [Full Text] [Related]  

  • 27. Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    BMC Cardiovasc Disord; 2021 Jul; 21(1):347. PubMed ID: 34289813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the benefit of sodium-glucose cotransporter inhibitors over heart failure progression on the kidney side?
    Gronda E; Iacoviello M; Gabrielli D; Caldarola P; Tavazzi L;
    Eur J Intern Med; 2022 Dec; 106():140-143. PubMed ID: 35985952
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 30. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
    Gulsin GS; Graham-Brown MPM; Squire IB; Davies MJ; McCann GP
    Heart; 2022 Jan; 108(1):16-21. PubMed ID: 33972360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis.
    López-Vilella R; Trenado VD; Cervera BG; Sánchez-Lázaro I; Bonet LA
    Eur J Intern Med; 2022 Oct; 104():128-130. PubMed ID: 35773170
    [No Abstract]   [Full Text] [Related]  

  • 32. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
    Liu T; Li R; Wang X; Gao X; Zhang X
    Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
    van der Aart-van der Beek AB; de Boer RA; Heerspink HJL
    Nat Rev Nephrol; 2022 May; 18(5):294-306. PubMed ID: 35145275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection Fraction.
    Al-Abdouh A; Mhanna M; Barbarawi M; Abusnina W; Gupta VA
    Am J Cardiol; 2022 Feb; 164():138-141. PubMed ID: 34799085
    [No Abstract]   [Full Text] [Related]  

  • 35. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
    Yaribeygi H; Butler AE; Atkin SL; Katsiki N; Sahebkar A
    J Cell Physiol; 2018 Jan; 234(1):223-230. PubMed ID: 30076706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation.
    Sano M
    Ther Adv Cardiovasc Dis; 2020; 14():1753944720939383. PubMed ID: 32715944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
    Patoulias D; Papadopoulos C; Stavropoulos K; Imprialos K; Doumas M
    Am J Cardiol; 2021 Jan; 138():116-118. PubMed ID: 33045203
    [No Abstract]   [Full Text] [Related]  

  • 39. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
    Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
    Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.